Online citations, reference lists, and bibliographies.

Pharmacokinetic Study Of Omeprazole In Elderly Healthy Volunteers

S. Landahl, T. Andersson, M. Larsson, B. Lernfeldt, P. Lundborg, C. Regårdh, E. Sixt, I. Skånberg
Published 1992 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
SummaryThe pharmacokinetics of omeprazole and its metabolites were studied in 8 healthy elderly volunteers using [14C]omeprazole. In another 6 healthy elderly volunteers, the pharmacokinetics of omeprazole were studied using unlabelled drug. Each volunteer received single doses of omeprazole intravenously (20mg) and orally (40mg) as solutions in a randomised crossover design. The plasma concentrations and urinary excretion of omeprazole and metabolites were followed for 24 and 96h, respectively.The results indicate that the average metabolic capacity of omeprazole is decreased in the elderly compared with that found in earlier studies of healthy young individuals. This was reflected in an increase in bioavailability from 56 to 76%, a reduction in mean systemic clearance by approximately 50% (0.25 L/min) and a prolongation of the mean elimination half-life from 0.7 to 1.0h compared with the young.Despite these findings, the considerable overlap in these parameters between young and old volunteers, together with data from previous pharmacodynamic studies and the wide therapeutic range of omeprazole, indicate that dosage reductions are not needed in the elderly.



This paper is referenced by
Najczęściej zadawane pytania dotyczące leczenia inhibitorami pompy protonowej
Tomasz Wocial (2011)
Acquired Loss of Function of CYP2C19 in Cancer Patients: Studies to Determine the Prevalence and the Possible Molecular Mechanisms of This Genotype- Phenotype Discordance
Kathryn Elisa Burns (2014)
10.1586/1744666X.1.4.511
Esomeprazole: potent acid suppression in the treatment of acid-related disorders
Andrea Morgner-Miehlke (2005)
10.1016/j.addr.2018.08.013
Physiologically based pharmacokinetic modelling to guide drug delivery in older people
M. Chetty (2018)
Long term use of proton pump inhibitors : is there an increase in fracture risk?
Rachel Renee Mutchler (2010)
10.3109/00498254.2010.494201
Influence of CYP2C19 and ABCB1 polymorphisms on plasma concentrations of lansoprazole enantiomers after enteral administration
Masatomo Miura (2010)
10.3999/JSCPT.45.105
Pharmacokinetics and Pharmacogenetics in Clinical Trials
Tomonori Tateishi (2014)
Evaluation of the effects of therapeutic hypothermia and cardiac arrest on specific cytochrome P450 isoform activity
Jiangquan Zhou (2011)
10.1038/ajg.2010.409
Treatment of GERD and Proton Pump Inhibitor Use in the Elderly: Practical Approaches and Frequently Asked Questions
Shannon Scholl (2011)
10.1124/dmd.112.045575
Evaluation of Six Proton Pump Inhibitors As Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19
T. Zvyaga (2012)
Hip Fracture Long-term Proton Pump Inhibitor Therapy and Risk of Correction
Y. Yang (2006)
10.1370/afm.1243
Use of Acid-Suppressive Drugs and Risk of Fracture: A Meta-analysis of Observational Studies
Chun-Sick Eom (2011)
10.1007/s00228-007-0331-3
Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration
Takenori Niioka (2007)
10.1016/S1871-5125(10)35004-7
Chapter 4 – Omeprazole
Abdullah A. Al-Badr (2010)
10.1001/jama.296.24.2947
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
Semantic Scholar Logo Some data provided by SemanticScholar